Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) Closed Significantly Below Its 50 Day Average

0
83

Company shares last traded at $1.41 which is significantly below the 50 day moving average which is $1.74 and slightly below the 200 day moving average of $1.44. The 50 day moving average went down by -19.07% whereas the 200 day moving average was down $-0.03 or -2.34%. 15K shares changed hands on Tuesday. Shares saw a steep decrease in trading volume of 96.93% under the normal average daily volume.

Traders are feeling more bullish on the company as indicated by the downtick in short interest. The company realized a fall in short interest between September 15, 2017 and September 29, 2017 of -0.90%. Short shares fell 29,539 over that period. Days to cover decreased -4.0 to 3.0 and the percentage of shorted shares is 0.05% as of September 29.

There has been some selling insider activity on Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) recently. James Patrick Tursi, Chief Medical Officer sold $24,900 worth of shares at an average price of $2.50 on October 2nd. Tursi now owns $643,375 of stock per an SEC filing yesterday.

The following firms have recently changed their position in ARLZ. As of quarter end Jw Asset Management, LLC had disposed of a total of 1,112,785 shares trimming its position 77.7%. The value of the investment in Aralez Pharmaceuticals Inc. decreased from $3,065,000 to $432,000 a change of 85.9% quarter over quarter. As of the end of the quarter Ubs Group Ag had sold 627 shares trimming its stake by 9.5%. The value of the total investment in Aralez Pharmaceuticals Inc. went from $14,000 to $8,000 a change of $6,000 since the last quarter.

Nwam LLC cut its ownership by selling 15,100 shares a decrease of 35.9% from 03/31/2017 to 06/30/2017. Nwam LLC owns 27,000 shares valued at $36,000. The total value of its holdings decreased 60.0%. As of quarter end Cutler Group LP had sold a total of 8,704 shares trimming its holdings by 93.6%. The value of the company’s investment in Aralez Pharmaceuticals Inc. decreased from $12,000 to $1,000 decreasing 91.7% for the reporting period.

As of the last earnings report the EPS was $-1.63 and is estimated to be $-1.62 for the current year with 66,848,000 shares currently outstanding. Next quarter’s EPS is forecasted to be $-0.38 and the next full year EPS is anticipated to be $-1.04.

Aralez Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada, Ireland, and the United States. The company engages in acquiring, developing, and commercializing products primarily in cardiovascular disease, pain, and other specialty areas. It offers Fibricor, a fenofibric acid for the treatment of severe hypertriglyceridemia; Cambia, a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks with or without aura in adults; Fiorinal and Fiorinal C for the relief of tension type headaches; Soriatane, a retinoid, an aromatic analog of vitamin A for the treatment of severe psoriasis and other disorders of keratinization; and Bezalip SR, a pan-peroxisome proliferator-activated receptor activator to treat hyperlipidemia, as well as to increase insulin sensitivity and decrease blood glucose levels for the patients with metabolic syndrome. The company also markets NeoVisc, a sodium hylauronic solution; Uracyst, a sodium chondroitin sulfate; Durela, a tramadol hydrochloride; Proferrin, a heme iron polypeptide; Resultz, a isopropyl myristate; Collatamp G, a collagen-gentamycin; and a portfolio of eight products targeted for the areas of gastroenterology and women’s health. In addition, it develops YOSPRALA 81/40 and 325/40 for secondary prevention of cardiovascular and cerebrovascular disease in patients at risk for gastric ulcers, which have completed Phase III clinical development in the United States; and Bilastine, an antihistamine drug for the treatment of allergic rhinoconjunctivitis and urticaria. Further, the company’s out-licensed products include VIMOVO for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, as well as to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers; and Treximet, a migraine medicine. Aralez Pharmaceuticals Inc. is headquartered in Milton, Canada. Aralez Pharmaceuticals Inc. .